The two companies have entered into a joint research agreement.
Under the agreement, Alligator will employ its antibody generation technologies in collaboration with BioArctic to develop new product candidates, it states in a press release.
“We are very pleased that BioArctic has recognized the power of Alligator’s proprietary phage display libraries which have been successfully used to generate Alligator’s suite of immuno-oncology programs. The application of this technology to the neurodegenerative field demonstrates the broad applicability of our powerful platform,” says Malin Carlsson, interim CEO of Alligator Bioscience.
“BioArctic’s focus is to develop new treatments to help patients with neurological diseases. We are looking forward to working together with Alligator, utilizing their phage display platform, in the development of new antibody therapeutic candidates with novel mechanisms of action,” says Johanna Fälting, Vice President and Head of Research at BioArctic.
Photo of Malin Carlsson, interim CEO, Alligator Bioscience and Johanna Fälting, Head of Research, BioArctic